TANDEM TRIAL: a factorial randomised controlled trial of dose and review schedule of bevacizumab (Avastin) for neovascular macular degeneration in the East Midlands.
Alexander J E FossRebecca HaydockMargaret ChildsLelia M DuleyTheo EmpeslidisSushma Dhar-MunshiAlan A MontgomeryReuben OgollahMara OzolinsPaul TeshaEleanor MitchellPublished in: BMJ open ophthalmology (2020)
The standard dose of bevacizumab can be halved without compromising efficacy. Bimonthly review cannot be considered to be no worse than monthly review.